661 related articles for article (PubMed ID: 26976646)
1. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
2. Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients.
Altieri M; Delaval G; Kimmoun E; Allaire M; Salamé E; Dumortier J
Exp Clin Transplant; 2018 Jun; 16(3):321-325. PubMed ID: 28697715
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation.
David-Neto E; Romano P; Kamada Triboni AH; Ramos F; Agena F; Almeida Rezende Ebner P; Altona M; Galante NZ; Brambate Carvalhinho Lemos F
Transplantation; 2017 Jun; 101(6):1365-1372. PubMed ID: 27482958
[TBL] [Abstract][Full Text] [Related]
5. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
Shin MH; Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Yun YI; Kim WJ; Kang WH; Kim SH; Jiang H; Lee S; Tak EY
Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
[TBL] [Abstract][Full Text] [Related]
6. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
Kim SH; Lee SD; Kim YK; Park SJ
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
[TBL] [Abstract][Full Text] [Related]
7. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial.
Fischer L; Trunečka P; Gridelli B; Roy A; Vitale A; Valdivieso A; Varo E; Seehofer D; Lynch S; Samuel D; Ericzon BG; Boudjema K; Karpf C; Undre N
Liver Transpl; 2011 Feb; 17(2):167-77. PubMed ID: 21280190
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
[TBL] [Abstract][Full Text] [Related]
12. Once-daily tacrolimus in living donor liver transplant recipients.
Sugawara Y; Miyata Y; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Yamashiki N; Kokudo N
Biosci Trends; 2011 Aug; 5(4):156-8. PubMed ID: 21914950
[TBL] [Abstract][Full Text] [Related]
13. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
15. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
17. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
18. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
[TBL] [Abstract][Full Text] [Related]
19. Adequate exposure to tacrolimus with sublingual administration in pediatric liver transplant patients.
Riva N; Galván ME; Cáceres-Guido P; Dip M; Licciardone N; Imventarza O; Schaiquevich P; Buamscha D
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):352-354. PubMed ID: 28079516
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy.
Ericzon BG; Varo E; Trunečka P; Fischer L; Colledan M; Gridelli B; Valdivieso A; O'Grady J; Dickinson J; Undre N
Clin Transplant; 2017 Jun; 31(6):. PubMed ID: 28295581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
